Genes A27L and F13L as Genetic Markers for the Isolation of Recombinant Vaccinia Virus.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 10 2019
30 10 2019
Historique:
received:
07
08
2019
accepted:
11
10
2019
entrez:
1
11
2019
pubmed:
2
11
2019
medline:
30
10
2020
Statut:
epublish
Résumé
After assembly in the cytosol, some Vaccinia virus particles go through a complex process that leads to virus egress and eventually cell-to-cell transmission. Intracellular particles are fully infectious, and therefore virus mutants lacking essential functions in the exit pathway are unable to form plaques but can multiply intracellularly. We isolated virus mutants in which two of the genes required for virus spread (F13L and A27L) were deleted independently or concurrently. The phenotypes of the mutant viruses were consistent with the need of A27L and F13L for intercellular virus transmission, the effect of the ΔA27L mutation being more severe than that of ΔF13L. Despite their defect in spread, ΔA27L mutant viruses could be expanded by infecting cell cultures at high multiplicity of infection, followed by the release of virions from infected cells by physical means. We developed a novel system for the isolation of recombinant Vaccinia virus in which selection is efficiently achieved by recovering plaque formation capacity after re-introduction of A27L into a ΔA27L virus. This system allowed the insertion of foreign DNA into the viral genome without the use of additional genetic markers. Furthermore, starting with a double mutant (ΔA27L-ΔF13L) virus, A27L selection was used in conjunction with F13L selection to mediate simultaneous dual insertions in the viral genome. This selection system facilitates combined expression of multiple foreign proteins from a single recombinant virus.
Identifiants
pubmed: 31666569
doi: 10.1038/s41598-019-52053-4
pii: 10.1038/s41598-019-52053-4
pmc: PMC6821840
doi:
Substances chimiques
Genetic Markers
0
Mutant Proteins
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15684Références
Methods Mol Biol. 2004;269:15-30
pubmed: 15114004
J Gen Virol. 2015 Aug;96(8):2360-2371
pubmed: 25972354
Expert Rev Vaccines. 2018 Oct;17(10):925-934
pubmed: 30300041
J Virol. 1991 Nov;65(11):5910-20
pubmed: 1920620
Virology. 1987 Aug;159(2):423-32
pubmed: 2441522
Nucleic Acids Res. 1990 Sep 25;18(18):5347-51
pubmed: 2216706
Proc Natl Acad Sci U S A. 1982 Dec;79(23):7415-9
pubmed: 6296831
J Virol. 1992 Jul;66(7):4170-9
pubmed: 1602540
J Virol. 2005 Apr;79(8):4755-63
pubmed: 15795261
Expert Opin Biol Ther. 2019 Jun;19(6):561-573
pubmed: 30919708
Chem Biol. 2008 Oct 20;15(10):1116-24
pubmed: 18940671
J Virol. 1989 Feb;63(2):997-1001
pubmed: 2911129
Nat Commun. 2018 Mar 26;9(1):1230
pubmed: 29581442
PLoS One. 2011;6(9):e24643
pubmed: 21931792
Virology. 1990 Sep;178(1):81-91
pubmed: 2389560
Proc Natl Acad Sci U S A. 1982 Aug;79(16):4927-31
pubmed: 6289324
Virol J. 2004 Nov 22;1:10
pubmed: 15555076
Biotechniques. 2001 Mar;30(3):524-6, 528-9
pubmed: 11252789
Nat Methods. 2010 Nov;7(11):893-5
pubmed: 20953177
Mol Ther Methods Clin Dev. 2017 Sep 30;7:112-122
pubmed: 29085848
Nat Methods. 2017 Jan;14(1):53-56
pubmed: 27869816
J Virol. 1990 Oct;64(10):4884-92
pubmed: 2398531
Gene. 1995 Jun 9;158(2):157-62
pubmed: 7607536
ACS Chem Biol. 2012 Nov 16;7(11):1848-57
pubmed: 22894855
J Gen Virol. 2000 Jan;81(Pt 1):47-58
pubmed: 10640541
J Virol. 1998 Feb;72(2):1577-85
pubmed: 9445060
J Gen Virol. 2013 Dec;94(Pt 12):2771-2776
pubmed: 24077296
Curr Protoc Mol Biol. 2017 Jan 5;117:16.17.1-16.17.18
pubmed: 28060405